CCN6 improves hepatic steatosis, inflammation, and fibrosis in non-alcoholic steatohepatitis.

Yiran SongChenyang LiYuxin LuoJinbo GuoYaxing KangFengrong YinLihong YeDonglei SunJun YuXiao-Lan Zhang

Published in: Liver international : official journal of the International Association for the Study of the Liver (2022)

CCN6 protects against hepatic steatosis, inflammation response and fibrosis by inhibiting the activation of ASK1 along with its downstream MAPK signalling. CCN6 may be a potential therapeutic target for the treatment of NASH.

Keyphrases

oxidative stress
signaling pathway
liver injury
cell proliferation
risk assessment
combination therapy
drug induced
climate change